A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.

Published online

Journal Article

BACKGROUND: High dose interleukin-2 (HD IL-2) can induce durable responses in a subset of patients leading to long-term survival. Immune checkpoint blockade (ICB) has demonstrated similarly durable responses in a larger proportion of patients. However, not all patients respond to immune checkpoint blockade and subsequent therapeutic options need to be explored. METHODS: The PROCLAIM database was queried for patients with metastatic melanoma who had received HD IL-2 after treatment with ipilimumab or without prior ICB. Patient characteristics, toxicity and efficacy were analyzed. RESULTS: A total of 52 metastatic melanoma patients were treated with high dose IL-2 after ipilimumab and 276 patients were treated with high dose IL-2 without prior ICB. The overall response rate in the prior ipilimumab group was 21 % as compared to 12 % in the group that had not received prior ipilimumab. The median overall survival, measured from the initiation of HD IL-2 therapy, was 19.3 months in the prior ipilimumab group and 19.4 months in the no prior ICB group. Toxicities observed on HD IL-2 were relatively equivalent between the groups although there were cases of CTLA4 antibody-induced colitis reported after HD IL-2 treatment and a CTLA4 antibody-induced colitis related death. CONCLUSION: In this retrospective analysis HD IL-2 therapy displayed antitumor activity in melanoma patients who progressed following treatment with ipilimumab. Most HD IL-2 toxicity was not worsened by prior ipilimumab therapy except for one treatment related death from colitis. Care should be taken to avoid reactivation of CTLA4 antibody-induced colitis.

Full Text

Duke Authors

Cited Authors

  • Buchbinder, EI; Gunturi, A; Perritt, J; Dutcher, J; Aung, S; Kaufman, HL; Ernstoff, MS; Miletello, GP; Curti, BD; Daniels, GA; Patel, SP; Kirkwood, JM; Hallmeyer, S; Clark, JI; Gonzalez, R; Richart, JM; Lutzky, J; Morse, MA; Sullivan, RJ; McDermott, DF

Published Date

  • 2016

Published In

Volume / Issue

  • 4 /

Start / End Page

  • 52 -

PubMed ID

  • 27660706

Pubmed Central ID

  • 27660706

International Standard Serial Number (ISSN)

  • 2051-1426

Digital Object Identifier (DOI)

  • 10.1186/s40425-016-0155-8

Language

  • eng

Conference Location

  • England